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Abstract

Key Points

IMPORTANCE Transitions between e-cigarettes and cigarettes are common among tobacco users,
but empirical evidence on the health outcomes of switching tobacco products is scarce.

Question Does exposure to tobaccorelated toxicants change when users
transition between cigarette,

OBJECTIVES To examine changes in urinary biomarkers between baseline and 1-year follow-up

e-cigarette, dual use, and no use?
Findings In this large-scale, longitudinal

among adult tobacco users switching between e-cigarettes and cigarettes.

cohort study, transitions from cigarettes

DESIGN, SETTING, AND PARTICIPANTS This cohort study used data from wave 1 (baseline,

or dual use to e-cigarettes or no use

September 2013 to December 2014) and wave 2 (1-year follow-up, October 2014 to October 2015) of

were associated with reduced exposure

the Population Assessment of Tobacco and Health Study. A subset of the probability sample of US

to toxicants. Switching from exclusive

adults who voluntarily provided biospecimens at 2 waves was analyzed. Participants were divided

cigarette use to dual use of cigarettes

into 3 mutually exclusive groups at baseline: exclusive cigarette smokers, exclusive e-cigarette users,

and e-cigarettes was not associated with

and dual users. Data analysis was performed in 2021.

a decrease in levels of toxicant
biomarkers in urine.

EXPOSURES Harmful and potentially harmful constituents included nicotine metabolites, tobaccospecific nitrosamines (TSNAs; including 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol [NNAL]),
metals, polycyclic aromatic hydrocarbons (PAHs), and volatile organic compounds (VOCs).

Meaning These findings may inform
regulatory strategies and public health
policies to guide tobacco users toward
harm reduction transition patterns.

MAIN OUTCOMES AND MEASURES Within-participant changes in 55 urinary biomarkers of
exposure (BOEs) to harmful and potentially harmful constituents were examined using multivariable
regression models.

+ Supplemental content

RESULTS Among 3211 participants (55.6% women, 68.3% White, 13.2% Black, and 11.8% Hispanic)

Author affiliations and article information are
listed at the end of this article.

at baseline, 21.9% of exclusive cigarette users, 42.8% of exclusive e-cigarette users, and 62.1% of
dual users changed product use at follow-up (all percentages are weighted). There was a significant
reduction in urine concentrations of TSNAs, PAHs, and VOCs when users transitioned from exclusive
cigarette to exclusive e-cigarette use, with a 92% decrease in NNAL, from a mean of 168.4 pg/mg
creatinine (95% CI, 102.3-277.1 pg/mg creatinine) to 12.9 pg/mg creatinine (95% CI, 6.4-25.7 pg/mg
creatinine; P < .001). A similar panel of BOEs decreased when dual users transitioned to exclusive
e-cigarette use; NNAL levels decreased by 96%, from a mean of 143.4 pg/mg creatinine (95% CI,
86.7-237.0 pg/mg creatinine) to 6.3 pg/mg creatinine (95% CI, 3.5-11.4 pg/mg creatinine; P < .001).
Nicotine metabolites, TSNAs, PAHs, and VOCs significantly increased when baseline exclusive
e-cigarette users transitioned to exclusive cigarette use or dual use. Switching from exclusive
cigarette use to dual use was not associated with significant decreases in BOEs.
CONCLUSIONS AND RELEVANCE This national cohort study provides evidence on the potential
harm reduction associated with transitioning from exclusive cigarette use or dual use to exclusive
e-cigarette use. e-Cigarettes tend to supplement cigarettes through dual use instead of cessation at
(continued)
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Abstract (continued)

the population level. Continuous monitoring of BOE at the population level and assessment of BOE
change by product transition are warranted, as well as defined adverse health outcomes.
JAMA Network Open. 2022;5(2):e2147891. doi:10.1001/jamanetworkopen.2021.47891

Introduction
The use of e-cigarettes (ie, vaping) has been increasing in the US.1,2 The electronic vaping device
simulates tobacco smoking by aerosolizing liquid solutions, usually containing nicotine, for users to
inhale.3 e-Cigarette companies have heavily promoted their products to cigarette smokers through
extensive marketing campaigns and the development of multiple generations of products, including
those with sleek designs, high nicotine concentration, and numerous flavors.4,5 Current smokers
reported a higher e-cigarette use prevalence (14.4%) compared with former smokers (7.6%) and
never smokers (1.4%).6
Transitions in tobacco use are common among e-cigarette users.7 Young adults (aged 18-24
years) are more likely to transition among tobacco products than older adults (aged $55 years).8
Tobacco use history and frequency (experimental vs established use) could also be associated with
the likelihood of product transition.8 Some transition patterns may provide net public health benefits
by substantially reducing exposure to toxic combustion compounds. Switching completely from
combustible cigarettes to e-cigarettes may provide meaningful health benefits for current smokers,
especially those who could not quit as the result of severe nicotine dependence, withdrawal
symptoms, or mental illness.9
In contrast, some transition patterns can lead to adverse health outcomes and increase the
susceptibility to tobacco-related morbidity and mortality. e-Cigarette use may elevate the risk for
former smokers to relapse to combustible cigarette smoking,10,11 or for never smokers, especially
youths and young adults, to initiate cigarette smoking.9,12 National sales data obtained from Nielsen
showed that nicotine concentrations in e-cigarette products sold in retail stores doubled in 5 years
(2013-2018).13 Laboratory studies also identified an increasing trend in high concentrations of
nicotine metabolites in urine biomarkers among e-cigarette users.14 High levels of nicotine exposure
can cause addiction, potentially adversely affect adolescent brain development, alter cognitive
function, and increase susceptibility to other addictive drugs.15 Transition to dual use remains
common among cigarette smokers.16 The National Academy of Sciences Engineering and Medicine
called for research to assess short- and long-term health consequences of e-cigarette use at the
population level.9 Thus, it is critical to tease out confounding effects between harm reduction
alternatives and risk catalysts among complex transition patterns between cigarette and ecigarette use.
Biomarkers of exposure (BOEs) to nicotine and other toxicants can provide objective measures
to assess the impact of tobacco product transition on the general population. Given that e-cigarettes
are relatively new to the market with rapidly evolving products and varying ingredients, the longterm health outcomes of e-cigarette use are still under investigation.12 BOEs to carcinogens,
respiratory toxicants, cardiovascular toxicants, reproductive or developmental toxicants, and
addictive constituents can serve as intermediate end points for comparative assessment of health
consequences of tobacco use.17,18 It is of public health interest to understand relative risks measured
by BOEs when users transition between cigarette and e-cigarette use. One study19 analyzed 48 adult
daily dual cigarette and e-cigarette users in Canada and found a significant decrease in levels of BOE
to toxicants, such as carbon monoxide, 1-hydroxypyrene, and 4-(methylnitrosamino)-1-(3-pyridyl)-1butanol (NNAL), when dual users transitioned to exclusive e-cigarette use or abstained from both
products. However, that study was limited to dual users at baseline, with a small sample size and a
short period of follow-up (ie, 3 consecutive 7-day periods). Evidence on changes of BOE from the
population-based sample with a comprehensive assessment of transition patterns in real-world
JAMA Network Open. 2022;5(2):e2147891. doi:10.1001/jamanetworkopen.2021.47891 (Reprinted)
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settings is needed to inform future public policies and interventions to reduce tobacco-related
chemical exposure.
To address gaps in knowledge, we conducted a longitudinal cohort study at the population level
to provide national estimates for changes in a wide range of 55 urine biomarkers across 5 classes of
harmful and potentially harmful constituents (HPHCs) in association with transition patterns
between cigarette and e-cigarette use from baseline to 1-year follow-up. We hypothesized that (1)
exposure to certain HPHCs would decrease when users transitioned from more harmful tobacco
products (eg, cigarettes or dual-use) to less harmful products (eg, e-cigarettes) or no use, (2) BOEs
would increase when users transitioned from exclusive e-cigarette use to cigarette use or dual use,
and (3) transition between exclusive cigarette use and dual use would not lead to a harm reduction.

Methods
Data
The Population Assessment of Tobacco and Health (PATH) Study is a longitudinal cohort study of
tobacco use among a nationally representative sample of US civilian, noninstitutionalized
individuals.20 The PATH study uses a 4-stage, stratified probability sampling design that intentionally
oversamples adult tobacco users, young adults, and African American individuals. Race and ethnicity
were derived from respondents’ answers to the PATH surveys and were assessed in this study as a
covariate. The wave 1 (baseline) adult data (32 320 respondents) were collected between September
2013 and December 2014, with a weighted household screener response rate of 54.0% and adult
interview response rate of 74.0%. The wave 2 (1-year follow-up) data (28 362 respondents) were
collected between October 2014 and October 2015, with a weighted retention rate of 83.1%.20 The
PATH data collection was conducted by Westat and approved by Westat’s institutional review board.
PATH participants provided written informed consent. This secondary data analysis of the PATH
study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
reporting guideline.
Adult respondents who completed the wave 1 interview were asked to provide urine and blood
samples voluntarily. Among 21 807 adults who provided a urine specimen at baseline, a stratified
sample of 11 522 respondents with sufficient urine for the biospecimen analyses were selected from
a diverse mix of tobacco use groups (the biomarker core) and sent for laboratory analysis. A majority
of respondents provided their urine sample less than 4 hours after completing the adult interview
(18 940 of 21 807 respondents [86.9%]), and a second visit was scheduled for the rest with a
separate computer mini-interview administered to collect data on recent nicotine exposure (ie,
today, yesterday, or the day before yesterday).21 At wave 2, urine biospecimens were requested
among the participants from the baseline biomarker core. The waves 1 and 2 PATH biomarker and
adult survey data were linked through the unique personal identifier.20,21 Further details regarding
the data collection, study design, and methods can be found in the PATH study user guide.20,21

Measures
The 55 biomarkers at waves 1 and 2 were grouped in 5 HPHC classes: (1) nicotine metabolites and
minor tobacco alkaloids, (2) tobacco-specific nitrosamines (TSNAs), (3) metals (heavy metals and
speciated arsenic), (4) polycyclic aromatic hydrocarbons (PAHs), and (5) volatile organic compounds
(VOCs). In the primary analysis, we selected a panel of 12 biomarkers (Table 1) that are most relevant
to the health effects of cigarette and e-cigarette use.16,22-26 Details of all 55 tobacco-related HPHC
biomarkers, assay principles, and clinical relevance to health outcomes are provided elsewhere.26
Biomarker concentrations below the limit of detection were imputed using a standard substitution
formula (the limit of detection divided by the square root of 2).27
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Tobacco Use Status at Both Waves
At baseline, those who reported currently using e-cigarettes every day or some days from the adult
interview or those who reported using e-cigarettes today, yesterday, or the day before yesterday
were classified as current e-cigarette users. Current cigarette users were similarly defined. On the
basis of the current use of e-cigarettes and cigarettes, we created 3 mutually exclusive groups:
exclusive cigarette users, exclusive e-cigarette users, and dual users. Similarly, we defined current
other tobacco use as those who reported using traditional cigars, cigarillos, filtered cigars, pipe,
hookahs, smokeless tobacco, snus, and dissolvable tobacco every day or some days or those who
reported using these products today, yesterday, or the day before yesterday.
Sociodemographic and other sample characteristics at wave 1 are described in eTable 1 in the
Supplement. As illustrated in the Figure, we excluded individuals with nicotine replacement
therapies in the past 3 days, or creatinine values outside the normal range of 10 to 370 mg/dL (291
individuals at baseline and 227 individuals at follow-up), current use of other tobacco products (3451
individuals at baseline and 279 individuals at follow-up), and no current use of cigarettes and
e-cigarettes at baseline (1844 individuals), resulting in 3211 respondents in the final analytical sample.

Statistical Analysis
Weighted estimates and 95% CIs of the transition probability from baseline to 1-year follow-up were
reported using wave 1 final person-level urinary specimen sampling weight and 100 replicate
weights. Variations were estimated using balanced repeated replication with a Fay coefficient of 0.3
for inference at the population level.28,29 Urinary biomarkers were calculated as a normalized ratio
of urinary creatinine concentration to control for variations in urine volume. Because of the skewness
in the distribution, BOE data were transformed using a natural log. Geometric means and 95% CIs of
creatinine-corrected biomarker concentration levels are reported.
Within-participant changes in BOE between baseline and follow-up were reported by tobacco
use status. Survey regressions were conducted to assess within-participant changes of
log(BOE/creatinine), adjusted by covariates (age, sex, race and ethnicity, and education).30 Statistical
analyses were performed using SAS statistical software version 9.4 (SAS Institute), and significance
was 2-tailed with adjustment for multiple comparisons using the Bonferroni method (.05/number of
comparisons). Data analysis was performed in 2021.

Results
At baseline, the 3211 participants were sociodemographically diverse (55.6% women, 68.3%
non-Hispanic White, 13.2% non-Hispanic Black, 11.8% Hispanic, 10.6% college graduates, and 92.5%
with annual income <$100 000; all percentages are weighted). Participants were classified into 3
mutually exclusive groups composed of 2356 exclusive cigarette users (79.7%), 210 exclusive
e-cigarette users (5.3%), and 645 dual users (15.0%). Sample characteristics, such as age, sex, race
and ethnicity, education, income, region, and use of tobacco products at home, were significantly
different across these 3 groups. Tobacco use history and frequency were largely similar across user
groups (eTable 1 in the Supplement).

Table 1. Weighted Prevalence of e-Cigarette and Cigarette Use Transitiona
Tobacco use status at wave 2, weighted % (95% CI)

a

Tobacco use at wave 1

Participants, No.

Weighted % (95% CI)

No use

Exclusive cigarette use

Exclusive e-cigarette use Dual use

Exclusive cigarette use

2356

79.7 (78-81.2)

10.4 (8.6-12.5)

78.2 (75.8-80.4)

1.2 (0.7-1.9)

10.3 (8.7-12.0)

Exclusive e-cigarette use

210

5.3 (4.5-6.2)

24.4 (18.2-31.9)

5.3 (3.0-9.3)

57.2 (49.2-64.9)

13.1 (8.8-18.9)

Dual use of cigarettes and
e-cigarettes

645

15.0 (13.7-16.5)

7.4 (5.5-10.0)

49.1 (43.6-54.8)

5.6 (3.7-8.2)

37.9 (32.9-43.1)

All analyses applied urinary sample weight, 100 replicated weights, and the balanced repeated replication method with Fay adjustment of 0.3 to account for the Population
Assessment of Tobacco and Health Study’s complex design.
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Transition in e-Cigarette and Cigarette Use
As shown in Table 1 (weighted percentages), 21.9% of baseline exclusive cigarette users changed
product use at follow-up: 10.3% switched to dual use, 1.2% transitioned to exclusive e-cigarette use,
and 10.4% transitioned to no-use. More than one-half (57.2%) of baseline exclusive e-cigarette users
maintained the same status, and 42.8% changed use: 24.4% stopped using e-cigarettes (cessation),
5.3% transitioned to exclusive cigarette users, and 13.1% became dual users at follow-up. Among dual
users at baseline, 62.1% changed product use: 49.1% transitioned to exclusive cigarette use, 7.4%
stopped using both products, and 5.6% became exclusive e-cigarette users at follow-up. Only 37.9%
maintained dual use status.

Changes in BOE Among Baseline Dual Users of Cigarettes and e-Cigarettes
On average, dual users had significant reductions in concentrations of TSNAs (eg, NNAL), PAHs (eg,
3-hydroxyfluorene and 1-hydroxypyrene), and VOCs after the transition to exclusive e-cigarette use
or nonuse (Table 2). Nicotine equivalence (TNE2) decreased by 97% from 3.6 nmol/mg creatinine
(95% CI, 1.1-12.0 nmol/mg creatinine) to 0.1 nmol/mg creatinine (95% CI, 0.03-0.4 nmol/mg
creatinine; P < .001) when baseline dual users transitioned to no use at follow-up. NNAL, a
metabolite of nicotine-derived nitrosamine ketone, decreased by 96% from 143.4 pg/mg creatinine
(95% CI, 86.7-237.0 pg/mg creatinine) to 6.3 pg/mg creatinine (95% CI, 3.4-11.4 pg/mg creatinine;

Figure. Flowchart for Population Assessment of Tobacco and Health (PATH) Study Participants Included
in the Analytical Sample
32 320 Participants (aged >18 y)
completed PATH wave 1 survey

11 522 Respondents with urinary specimen
(PATH wave 1 biomarker file)

291 Excluded
Participants reported using nicotine
replacement therapies in the past 3 d or
those with creatinine levels ≤10 mg/dL
or >370 mg/dL

28 362 Participants completed
PATH wave 2 adult survey

11 231 Participants with linked adult
file and biomarker file

9012 Respondents with urinary specimen
(PATH wave 2 biomarker file)

227 Excluded
Participants reported using nicotine
replacement therapies in the past 3 d or
those with creatinine levels ≤10 mg/dL
or >370 mg/dL

8785 Participants with linked wave 1
and wave 2 data

3451 Excluded
Participants reported current use of
other tobacco products at baseline
1844 Participants who reported no
cigarette or e-cigarette use at
baseline
279 Participants reported current
use of other tobacco products
at follow-up

3211 Baseline current cigarette or
e-cigarette users in the final
analytical sample
2356 Exclusive cigarette users
210 Exclusive e-cigarette users
645 Dual users
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.27
.01

<.001d

<.001d

.02

.002d

.02

<.001d

144.3
(132.9-156.7)
319.1
(289.4-351.9)
152
(130.4-177.1)

.001d

.05

.33

15.4
(14.5-16.5)
0.64
(0.57-0.71)
0.4
(0.3-0.4)

.96

.81

.01

0.28
(0.25-0.31)
0.49
(0.45-0.55)

.05

266.2
(225.8-313.8)
12.1
(10.2-14.4)

2690.0
(2260.93200.7)

42.6
(36.8-49.4)

Wave 1

.51

.14

.004d

<.001d

<.001d

<.001d

<.001d

<.001d

<.001d

Adj. P
valueb

P
valueb

133.4
(124.2-143.3)
294.4
(266.1-325.7)
141.2
(122.3-163)

15.5
(14.3-16.8)
0.63
(0.56-0.72)
0.3
(0.3-0.4)

0.31
(0.28-0.34)
0.48
(0.43-0.53)

256.8
(217.5-303.1)
11.3
(9.9-12.9)

2627.9
(2206.53129.7)

41.2
(35.5-47.9)

Wave 2

Adj. P
P
valueb valueb

.28

.06

.07

.13

.94

.92

.36

.01

.53

.55

.77

.78

a

All analyses applied urinary sample weight, 100 replicated weights, and the balanced repeated replication
method with Fay adjustment of 0.3 to account for the Population Assessment of Tobacco and Health Study’s
complex design.

Abbreviations: 1-PYR, 1-hydroxypyrene; 2-NAP, 2-naphthol or 2-hydroxynaphthalene; 3-FLU, 3-hydroxyfluorene;
AAMA, N-acetyl-S-(2-carbamoylethyl)-L-cysteine (acrylamide); Adj, adjusted; CEMA, N-acetyl-S-(2-carboxyethyl)L-cysteine (acrolein); CYMA, N-acetyl-S-(2-cyanoethyl)-L-cysteine (acrylonitrile); NNAL, 4-(methylnitrosamino)1-(3-pyridyl)-1-butanol; NNN, N'-nitrosonornicotine; PAH, polycyclic aromatic hydrocarbon; TNE2, nicotine
equivalence; TSNA, tobacco-specific nitrosamine; VOC, volatile organic compound.
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Significant at P < .0042 with adjustment for multiple comparisons using the Bonferroni method
(0.05/12 = .0042).
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.09

.09

.13

.23
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Refers to the molar sum of the imputed values of cotinine and trans-3′-hydroxycotinine in urine.
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(296.2-351.5)
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(13.9-17.1)
0.69
(0.62-0.76)
0.4
(0.3-0.4)

0.34
(0.3-0.38)
0.51
(0.47-0.56)

.36

.35
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d

<.001d

149.1
(137.9-161.2)
323.8
(294-356.7)
160.1
(139.7-183.5)

14.9
(14-16)
0.67
(0.61-0.74)
0.4
(0.3-0.4)

0.3
(0.27-0.34)
0.48
(0.44-0.53)

305.5
(267.8-348.4)
14.1
(12.1-16.5)

3178.8
(2723.43710.3)

47.9
(41.1-55.9)

Wave 1

c

<.001d

<.001d

<.001d

<.001d
<.001d

.001d

<.001d

.07

.26

.62

.48

<.001d

.01

.01

Adj. P
valueb

<.001d

<.001d

<.001d

.78

.11

.15

<.001d

.02

.02

P
valueb

P value was generated from univariate regression analysis to compare within-participant change of log
(biomarkers of exposure/creatinine). Adjusted P value was generated from multivariable linear regressions,
adjusted by demographic covariates (age, sex, race and ethnicity, and education).

45.4
(37.7-54.7)
93.2
(71.9-120.7)
3.7
(2.1-6.3)

5.9
(4.4-8.0)
0.09
(0.05-0.14)
0.1
(0.1-0.2)

0.36
(0.26-0.49)
0.6
(0.4-0.8)

6.3
(3.5-11.4)
6.6
(3.9-11.1)

1192.4
(487.12918.8)

16.4
(6.7-40.0)

Wave 2

Dual use at wave 2 (n = 252)
Geometric mean (95% CI)

b

123.7
(100.2-152.6)
243.0
(176.1-335.2)
82.2
(47.5-142.4)

13.5
(10.8-16.9)
0.46
(0.31-0.69)
0.3
(0.2-0.3)

0.3
(0.21-0.43)
0.6
(0.48-0.75)

143.4
(86.7-237)
9.1
(6.4-13.1)

2791.8
(1697.44591.9)

38.7
(23.8-62.8)

Wave 1

Geometric mean (95% CI)

Heavy
metals,
ng/mg
creatinine
Cadmium 0.16
(0.11-0.22)
Lead
0.45
(0.36-0.55)
PAHs,
ng/mg
creatinine
2-NAP
7.6
(5.6-10.2)
3-FLU
0.21
(0.14-0.32)
1-PYR
0.2
(0.1-0.3)
VOCs,
ng/mg
creatinine
AAMA
81.9
(64.3-104.3)
CEMA
161.0
(122.7-211.2)
CYMA
28.4
(13.3-60.7)

NNN

TSNAs,
pg/mg
creatinine
NNAL

Biomarkers
Urinary
nicotine
metabolites,
ng/mg
creatinine
TNE2,
nmol/mg
creatininec
Cotinine

e-Cigarette only at wave 2 (n = 36)
Geometric mean (95% CI)

Cigarette only at wave 2 (n = 315)
Geometric mean (95% CI)

No use at wave 2 (n = 42)

Table 2. Urinary Biomarkers Among Dual Users at Wave 1a
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P < .001). Multiple biomarkers of VOCs reduced by more than one-half when dual users transitioned
to exclusive e-cigarette use at follow-up (Table 2).

Changes in BOE Among Baseline Exclusive e-Cigarette Users
Mean concentration levels of TSNAs (eg, NNAL), PAHs (eg, 3-hydroxyfluorene), and VOCs (eg,
N-acetyl-S-(2-carbamoylethyl)-L-cysteine, N-acetyl-S-(2-carboxyethyl)-L-cysteine, and
N-acetyl-S-(2-cyanoethyl)-L-cysteine) significantly increased when exclusive e-cigarette users
transitioned to exclusive cigarette use or dual use (Table 3). Urinary nicotine metabolites, including
TNE2 and cotinine, increased by more than 3-fold when exclusive e-cigarette users transitioned to
dual use at follow-up. The biomarker of VOC (ie, N-acetyl-S-(2-cyanoethyl)-L-cysteine/acrylonitrile)
increased by 621% from 17.3 ng/mg creatinine (95% CI, 5.4-54.8 ng/mg creatinine) to 125.9 ng/mg
creatinine (95% CI, 61.8-256.6 ng/mg creatinine; P < .001), and the biomarker of PAH (ie, 2-naphthol)
increased by 155% from 8.5 ng/mg creatinine (95% CI, 5.9-12.2 ng/mg creatinine) to 13.2 ng/mg
creatinine (95% CI, 9.6-18.2 ng/mg creatinine; P < .001) when exclusive e-cigarette users
transitioned to exclusive cigarette use.

Changes in BOE Among Baseline Exclusive Cigarette Users
The concentrations of nicotine metabolites (eg, TNE2 or cotinine), TSNAs (eg, NNAL), and PAHs (eg,
2-naphthol, 1-hydroxypyrene) were significantly lower when exclusive cigarette users transitioned
to nonuse at follow-up (Table 4). The concentrations of TSNAs, PAHs, and VOCs were also
considerably lower when exclusive cigarette users transitioned to exclusive e-cigarette use, with
NNAL decreasing by 92% from 168.4 pg/mg creatinine (95% CI, 102.3-277.1 pg/mg creatinine) to 12.9
pg/mg creatinine (95% CI, 6.4-25.7 pg/mg creatinine; P < .001) and N-Acetyl-S-(2-carboxyethyl)-Lcysteine (acrolein) decreasing by 57% from 250.9 ng/mg creatinine (95% CI, 188.0-334.9 ng/mg
creatinine) to 107.6 ng/mg creatinine (95% CI, 81.2-142.5 ng/mg creatinine; P < .001). The
concentrations of BOE were not significantly different when exclusive cigarette users transitioned to
dual use. Changes of 55 biomarkers across 5 HPHC classes are listed in eTable 2, eTable 3, and
eTable 4 in the Supplement, with the results largely consistent with the primary analyses of 12
biomarkers.

Discussion
This cohort study identified multiple biomarkers of nicotine metabolites, TNSAs, VOCs, and PAHs
that showed consistent change patterns and large effect sizes that reflect population-level health
outcomes. Cigarettes and e-cigarettes are the top 2 tobacco products used by US adults, with 34.1
million current cigarette smokers and 10.9 million current e-cigarette users.2 We found complex
patterns and heterogeneous health outcomes associated with transitions between cigarettes and
e-cigarettes.
According to biospecimen measures, the health outcomes associated with cigarette and
e-cigarette transition can be classified into 3 categories: harm reduction, risk catalyst, and no change.
The results of urinary biospecimen analysis indicate the harm reduction associated with transitions
from dual use or exclusive cigarette use to exclusive e-cigarette use and transitions from any tobacco
use to no use. For instance, NNAL decreased by 96% for the transition from dual use to exclusive
e-cigarette use and by 92% for the transition from exclusive cigarette use to exclusive e-cigarette
use. Evidence in animal and human studies suggests that nicotine-derived nitrosamine ketone and
NNAL are potent lung carcinogens.24,31 e-Cigarettes heat liquids containing nicotine, glycerol, and
propylene glycol to create an aerosol for users to inhale, and those aerosols generally contain
substantially lower concentrations of toxic chemicals than combustible cigarettes.32 Metabolomic
profiling analysis shows reduced levels of oxidative stress and xenobiotics and improved vitamin
metabolism for smokers who switched to e-cigarettes.33
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0.07
(0.05-0.09)

0.1
(0.1-0.2)

3-FLU

1-PYR

100.2
(81.9-122.5)

3.6
(2.0-6.5)

CEMA

CYMA

2.1
(1.3-3.5)

90.5
(77-106.4)

46.3
(39.1-54.7)

0.1
(0.1-0.1)

0.06
(0.04-0.08)

4.6
(3.5-6.2)

0.36
(0.28-0.47)

0.14
(0.1-0.18)

1.7
(1.3-2.1)

3.0
(1.6-5.4)

.04

.203

.06

.10

.69

.26

.98

.31

.126

.18

.22

.08

.05

.20

.96

.67

.77

.31

.69

.28

<.001d

.07

.38

Adj. P
valueb

<.001d

P
valueb

17.3
(5.4-54.8)

159.6
(116-219.4)

84
(57.7-122.4)

0.2
(0.1-0.3)

0.11
(0.06-0.22)

8.5
(5.9-12.2)

0.59
(0.34-1.05)

0.24
(0.12-0.48)

6.0
(2.5-14.7)

32.7
(10.1-105.7)

501.9
(84.22991.3)

7.23
(1.32-39.74)

Wave 1

P valueb

<.001d

.04

.00

.02

.06

.20

.70

.01

.08

125.9
(61.8-256.6)

<.001d

257.7
.01
(183.3-362.3)

126.7
(93.5-171.9)

0.3
(0.2-0.4)

0.48
(0.33-0.69)

13.2
(9.6-18.2)

0.45
(0.26-0.78)

0.27
(0.14-0.53)

8.6
(3.9-18.9)

152.6
(78.8-295.2)

1941.7
(13052889.1)

30.59
.05
(18.97-49.35)

Wave 2

Adj. P
valueb

a

All analyses applied urinary sample weight, 100 replicated weights, and the balanced repeated replication
method with Fay adjustment of 0.3 to account for the Population Assessment of Tobacco and Health Study’s
complex design.

.20

.48

.57

43.3
(18.8-99.7)

<.001d

<.001d

.02

<.001d

Significant at P < .0042 with adjustment for multiple comparisons using the Bonferroni method
(0.05/12 = .0042).

10.3
(5.4-19.6)

<.001d

.002

<.001d

<.001d
.09

.01

.49

.12

.17

<.001d

.001d

.21

.61

.99

.16

<.001d

<.001d

203.8
<.001d
(164.8-252.1)

107.4
(82.1-140.7)

0.2
(0.1-0.3)

0.25
(0.15-0.41)

6.5
(4.4-9.7)

0.4
(0.32-0.49)

0.17
(0.13-0.23)

5.1
(3.4-7.9)

62.0
(26.1-147.3)

2568.6
(1815.73633.9)

Refers to the molar sum of the imputed values of cotinine and trans-3′-hydroxycotinine in urine.

.70

111.5
(84.9-146.6)

54.9
(43.6-69)

0.1
(0.1-0.2)

0.09
(0.06-0.14)

4.9
(3.7-6.5)

0.38
(0.29-0.49)

0.17
(0.12-0.25)

3.6
(2.6-5.1)

14.5
(7.7-27.2)

971.6
(591.91594.9)

<.001d

Adj. P
valueb

d

.06

.13

.63

.82

.67

.15

.94

.72

.93

.58

.85

P
valueb

46.68
<.001d
(34.79-62.63)

Wave 2

c

3.2
(2.4-4.5)

100.0
.51
(85.2-117.4)

57.1
(47.9-68.1)

0.2
(0.1-0.2)

0.09
(0.07-0.11)

.83

.08

.75

.83

.04

.02

17.97
(11.32-28.52)

Wave 1

P value was generated from univariate regression analysis to compare within-participant change of log
(biomarkers of exposure/creatinine). Adjusted P value was generated from multivariable linear regressions,
adjusted by demographic covariates (age, sex, race and ethnicity, and education).

4.2
(3.1-5.8)

106.1
(92.4-121.9)

62.9
(53.2-74.3)

0.2
(0.1-0.2)

0.09
(0.07-0.11)

5.6
(4.8-6.6)

0.4
(0.4-0.5)

0.25
(0.21-0.3)

4.4
(3.4-5.7)

4.2
(3.1-5.6)

469.5
(200.21101)

.98

Adj. P
P
valueb valueb

7.46
.03
(3.35-16.62)

Wave 2

Dual use at wave 2 (n = 31)
Geometric mean (95% CI)

b

<.001d

.57

<.001d

.91

.05

5.5
(4.7-6.5)

0.46
(0.39-0.55)

<.001d

<.001d

0.24
(0.2-0.3)

4.2
(3.5-5.2)

<.001d

.01

5.9
(4.1-8.3)

726.7
(359.81467.7)

11.38
(5.89-21.96)

Wave 1

<.001d

<.001d

<.001d

Abbreviations: 1-PYR, 1-hydroxypyrene; 2-NAP, 2-naphthol or 2-hydroxynaphthalene; 3-FLU, 3-hydroxyfluorene;
AAMA, N-acetyl-S-(2-carbamoylethyl)-L-cysteine (acrylamide); Adj, adjusted; CEMA, N-acetyl-S-(2-carboxyethyl)L-cysteine (acrolein); CYMA, N-acetyl-S-(2-cyanoethyl)-L-cysteine (acrylonitrile); NNAL, 4-(methylnitrosamino)1-(3-pyridyl)-1-butanol; NNN, N'-nitrosonornicotine; PAH, polycyclic aromatic hydrocarbon; TNE2, nicotine
equivalence; TSNA, tobacco-specific nitrosamine; VOC, volatile organic compound.

56.3
(45.8-69.3)

AAMA

VOCs, ng/mg
creatinine

5.6
(4.4-7.2)

2-NAP

PAHs, ng/mg
creatinine

0.12
(0.08-0.18)

Cadmium

Heavy
metals,
ng/mg
creatinine

4.6
(2.4-8.6)

NNAL

TSNAs,
pg/mg
creatinine

2.4
(0.8-6.8)

15.9
(5.1-49.7)

Cotinine

Wave 2

0.04
(0.02-0.12)

Wave 1

Geometric mean (95% CI)

TNE2,
0.27
nmol/mg
(0.09- 0.79)
c
creatinine

Urinary
nicotine
metabolites,
ng/mg
creatinine

Biomarkers

e-Cigarette only at wave 2 (n = 121)
Geometric mean (95% CI)

Cigarette only at wave 2 (n = 14)
Geometric mean (95% CI)

No use at wave 2 (n = 44)

Table 3. Urinary Biomarkers Among Exclusive e-Cigarette Users at Wave 1a
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0.21
(0.16-0.28)

0.2
(0.2-0.2)

3-FLU

1-PYR

Adj. P
valueb

24.9
(16.4-37.7)

4.3
(3.3-5.7)

<.001d
.01

.27

0.3 (0.3-0.3)

0.65
(0.62-0.69)

15.3
(14.6-16)

0.49
(0.47-0.51)

0.33
(0.3-0.35)

12.5
(11.4-13.8)

.13

.94

.92

.36

.01

.53

143.1
143.4
.28
(132.7-154.4) (133.3-154.3)

290.1
292.0
.06
(270.4-311.2) (276.2-308.6)

.46

.07

.96

.06

.86

.59

.41

.12

.74

.32

.63

.60

a

All analyses applied urinary sample weight, 100 replicated weights, and the balanced repeated replication
method with Fay adjustment of 0.3 to account for the Population Assessment of Tobacco and Health Study’s
complex design.

Abbreviations: 1-PYR, 1-hydroxypyrene; 2-NAP, 2-naphthol or 2-hydroxynaphthalene; 3-FLU, 3-hydroxyfluorene;
AAMA, N-acetyl-S-(2-carbamoylethyl)-L-cysteine (acrylamide); Adj, adjusted; CEMA, N-acetyl-S-(2-carboxyethyl)L-cysteine (acrolein); CYMA, N-acetyl-S-(2-cyanoethyl)-L-cysteine (acrylonitrile); NNAL, 4-(methylnitrosamino)1-(3-pyridyl)-1-butanol; NNN, N'-nitrosonornicotine; PAH, polycyclic aromatic hydrocarbon; TNE2, nicotine
equivalence; TSNA, tobacco-specific nitrosamine; VOC, volatile organic compound.

CYMA

168.4
104.4
.002d
(144.6-196.2) (92.9-117.5)

CEMA

.01

.77

140.6
140.5
.07
(134.7-146.8) (134.2-147.1)

0.3 (0.3-0.3)

<.001d

.33

0.62
(0.58-0.65)

.02

14.6
(13.9-15.3)

0.49
(0.47-0.51)

0.31
(0.29-0.33)

12.6
(11.7-13.6)

<.001d
.02

2264.7
(2069.22478.7)

.78

P
valueb

240.5
243.1
.55
(221.2-261.4) (225.1-262.5)

2272.5
(2076.42487)

.001d

.96

Wave 2

35.2
35.19
(32.17-38.52) (32.1-38.58)

Wave 1

.05

.81

.05

.14

.004d

.51

<.001d

<.001d

<.001d

<.001d

<.001d

Adj. P
valueb

<.001d

P
valueb

89.7
(79.3-101.5)

58.8
(53.1-65)

0.2
(0.2-0.2)

0.1
(0.08-0.12)

6.5
(5.8-7.2)

0.4
(0.37-0.45)

0.2
(0.17-0.23)

2.7
(2.3-3.1)

5.3
(3.9-7.1)

4.8
(3.1-7.5)

0.08
(0.05-0.12)

Wave 2

AAMA

VOCs, ng/mg
creatinine

8.3
(7.2-9.7)

2-NAP

PAH, ng/mg
creatinine

0.19
(0.16-0.22)

Cadmium

Heavy
metals,
ng/mg
creatinine

32.5
(20.5-51.6)

NNAL

TSNAs,
pg/mg
creatinine

2.48
(1.19-5.15)

Wave 1

Wave 2

713.0
(346.31468.2)

<.001d

.07

.26

.62

.48

.50

.94

.22

.24

.13

.51

.09

.09

.13

.23

.02

.36

.35

.30

.32

Significant at P < .0042 with adjustment for multiple comparisons using the Bonferroni method
(.05/12 = .0042).

130.2
(109.7-154.6)

320.2
(284.4-360.4)

135.5
(124.2-147.8)

.79

.63

.47

.13

.01

.99

.08

.31

.27

Adj. P
P
valueb valueb

Refers to the molar sum of the imputed values of cotinine and trans-3′-hydroxycotinine in urine.

168.4
(148.8-190.7)

316.6
(281.6-355.9)

147.4
(134.4-161.8)

0.3
(0.3-0.3)

0.62
(0.55-0.71)

14.6
(13.2-16.2)

0.43
(0.38-0.48)

0.29
(0.24-0.35)

13.3
(10.4-17.1)

236.6
(195.2-286.8)

2521.5
(2043.43111.4)

38.78
(31.68-47.46)

Wave 2

d

<.001d

<.001d

<.001d

0.3
(0.3-0.4)

0.68
(0.61-0.76)

16
(14.6-17.6)

0.46
(0.41-0.51)

0.3
(0.26-0.34)

15.5
(12-20.2)

278.7
(238-326.5)

3067.9
(2618.53594.4)

45.76
(39.53-52.96)

Wave 1

c

<.001d

<.001d

<.001d

<.0001 .001d

.01

<.001d

.78

.11

.15

<.001d

.01

.01

Adj. P
valueb

P value was generated from univariate regression analysis to compare within-participant change of log
(biomarkers of exposure/creatinine). Adjusted P value was generated from multivariable linear regressions,
adjusted by demographic covariates (age, sex, race and ethnicity, and education).

7.9
(5-12.6)

107.6
(81.2-142.5)

59.1
(48.1-72.5)

0.1
(0.1-0.1)

0.12
(0.08-0.17)

4.4
(3.5-5.4)

0.3
(0.2-0.5)

0.23
(0.15-0.33)

2.5
(1.6-3.9)

<.001d

.02

.02

P
valueb

Dual use at wave 2 (n = 257)
Geometric mean (95% CI)

b

103.8
(67.4-159.7)

250.9
(188-334.9)

109
(81.7-145.4)

0.3
(0.2-0.3)

0.52
(0.38-0.7)

11.6
(8.7-15.6)

0.32
(0.22-0.47)

0.22
(0.15-0.33)

13.6
(8.9-20.6)

168.4
12.9
(102.3-277.1) (6.4-25.7)

1833.2
(1003.33349.6)

25.6
10.48
(14.93-43.91) (5.07-21.69)

Wave 1

Geometric mean (95% CI)

TNE2,
nmol/mg
creatininec

Urinary
nicotine
metabolites,
ng/mg
creatinine

Biomarkers

e-Cigarette only at wave 2 (n = 32)
Geometric mean (95% CI)

Cigarette only at wave 2 (n = 1820)
Geometric mean (95% CI)

No use at wave 2 (n = 247)

Table 4. Urinary Biomarkers Among Exclusive Cigarette Users at Wave 1a
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e-Cigarettes may be appealing to combustible cigarette smokers as an alternative because they
provide nicotine as well as sensations that mirror those of combustible cigarettes, such as stimulation
of the respiratory tract and the inhalation and exhalation sequence.32,34 However, our study shows
that only a small percentage of baseline exclusive cigarette smokers and dual users transitioned to
exclusive e-cigarette use at follow-up (1.2% and 5.6%, respectively), which could limit benefits in
moving combustible cigarette smokers to less hazardous, noncombustible e-cigarettes.35 This may
be associated with the low effectiveness in early generations of e-cigarettes in delivering nicotine,
lack of knowledge among cigarette users to distinguish harmful effects between dual use and
exclusive e-cigarette use,36,37 or the effects of negative public health messaging.38
This study also provides health implications for the risk catalyst categories composed of
transitions from exclusive e-cigarette use to cigarette use or dual use. These transitions are
associated with increases of BOE in moderate to large effect sizes across TSNAs, PAHs, and VOCs,
which have been shown to be associated with adverse health outcomes, with extensive evidence in
cigarette studies24,39,40 and emerging evidence in e-cigarette studies for the association of BOE with
adverse health outcomes.26 TNSAs are toxic constituents derived from tobacco leaves, especially
during the curing process by nitrosation of amines.41-43 VOCs are formed during the incomplete
combustion of organic materials. Our study found an increase of acrylonitrile in the transition of
exclusive e-cigarette use to cigarette use or dual use. Acrylonitrile, produced by catalytic
ammoxidation of propylene, has been listed as a carcinogen and respiratory toxicant by the US Food
and Drug Administration.25 Long-term exposure to TSNAs, PAHs, and VOCs may increase the risk of
leukemia, bladder cancer, birth defects, and neurocognitive impairment.24,39,40
We found that approximately one-quarter of exclusive e-cigarette users quit vaping 1 year later
in comparison to 5.3% transitioning to exclusive cigarette smokers and 13.1% becoming dual users.
Although most (60.7%) current e-cigarette users planned to quit e-cigarettes, only 15.2% reported
past-year quit attempts.44 e-Cigarette use is not harmless12,16 and has been associated with
respiratory symptoms and abnormal heart rate variability among habitual e-cigarette users and
elevated cellular oxidative stress among short-term users.45,46 Unlike smoking cessation with
behavioral and pharmacological treatments,37 vaping cessation interventions are not widely
available, and there is a lack of empirical evidence regarding their effectiveness.25,40
Our study does not provide evidence to support that transition from exclusive cigarette
smoking to dual use of cigarettes and e-cigarettes results in harm reduction. Ideally, dual use may
represent an interim phase when cigarette users transition from combustible smoking to e-cigarette
use. Instead, our study shows that a majority of dual users maintained their dual-use status (37.9%)
or transitioned back to exclusive cigarette use (49.1%) 1 year later. This is concerning since
concentrations of BOE were largely unchanged for these tobacco users between baseline and
follow-up. Furthermore, a larger number of exclusive cigarette smokers transitioned to dual use than
to exclusive e-cigarette use 1 year later (10.3% vs 1.2%), suggesting that e-cigarettes may appeal to
cigarette smokers as a complementary product instead of a replacement for combustible cigarettes,
resulting in a small or no gain in harm reduction.

Limitations
This study has limitations. First, some biomarker outcomes with long half-lives (eg, metals) may come
from prior combustible tobacco use, passive tobacco exposure, or other sources.22 However, most
biomarkers analyzed in the study have a short half-life,22 and we removed other tobacco users in
both waves to avoid confounding effects. Second, we did not include tobacco use history in the
analysis because we focused on within-participant changes from baseline to follow-up. Third, we only
included the first 2 waves of the PATH data. Although the third wave of PATH biomarker data are
available, there were fewer biomarkers available for analysis. Previous studies in tobacco initiation,
progression, cessation, and relapse showed that 1 year is a critical milestone in tobacco transition.
Thus, the analysis of baseline and 1-year follow-up could measure a direct health impact on
behavioral changes. Fourth, the analyses were based on the data collected between 2013 and 2015.
JAMA Network Open. 2022;5(2):e2147891. doi:10.1001/jamanetworkopen.2021.47891 (Reprinted)
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The e-cigarette market has rapidly evolved since then with new generations of vaping devices, such
as JUUL and Puff Bars, which have higher concentrations of nicotine and various forms of nicotine
(eg, synthetic nicotine and nicotine salts).13 Biomarker outcomes may vary by e-cigarette device,
liquid solution, and flavors of e-liquid. Continued monitoring of BOE at the population level and
assessment of BOE change by e-cigarette products are warranted.

Conclusions
This study provides evidence suggesting that changes in biomarkers of tobacco toxicant exposure
occur in cases of transitions between cigarette smoking and e-cigarette use among US adults. Our
findings demonstrate the benefits of transitioning from combustible cigarette smoking to less
harmful e-cigarette use. However, most e-cigarette users continue to maintain dual use of cigarettes
and e-cigarettes or transition back to cigarette smoking, thus limiting the public health benefits
associated with switching to less harmful e-cigarette use.
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